FDA Approves New Targeted Drug Showing Major Survival Benefit in Advanced Pancreatic Cancer
August 27, 2026 The U.S. Food and Drug Administration has approved Rasonque (daraxonrasib), a new targeted medicine developed by Revolution...
Revolution Medicines
